AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu

23rd December 2019 Uncategorised 0

For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition. AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help that tough-to-treat population––and the FDA agreed to give it a shot despite a shaky safety profile. 

More: AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu
Source: fierce